Pharmaceutical
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
StemRIM Announces Patent Registration (Australia) for Redasemtide, as an Additional Therapeutic Indication of Cartilage Disorders
About this update from Stemrim Inc.
Stemrim Inc. (4599) Press ReleaseView Attachment